MET and central nervous system cancer: Interestingly, in non-xenograft-forming gliomas only IDH1 and TP53 or CIC mutations were detected; in contrast, in xenograft-forming gliomas, in addition to these mutations, additional mutations at the level of PI3KCA or amplification of PDGFRA, MET, or N-MYC have been detected [146].